Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naldemedine for Recurrent Acute Pancreatitis
NCT04966559Phase 3Active, not recruiting
- Start
- Jan 2022
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in acute pancreatitis (AP) comparing Naldemedine treatment with Placebo treatment (2 arms). Primary endpoint: Number of AP attacks verified by the Atlanta Criteria. Started Jan 2022; status: active, not recruiting.
02
Drugs
naldemedine
03
Conditions
acute pancreatitis (AP)
Beyond the preview
Go deeper on NCT04966559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04966559.